Company intelligence / Profile preview

TCM Biotech International Corp.

New Taipei City, New Taipei, Taiwantcmbio.com ↗

Ownership: Private
Development stage: Phase 3

Overview

TCM Biotech has received US FDA Orphan Drug Designation and is conducting Phase I/II clinical trials for its lead therapeutic targeting intermediate and advanced liver cancer. The company also offers a precision diagnostic platform for early detection of liver cancer and is developing an oral drug to repair urethral wall damage[1].

Therapeutic areas: OncologyMen's Health
Modalities: Small moleculesPrecision diagnosticsCombination therapies (e.g., with TACE)
Industry: Biotech

Drug pipeline

3 assets

Compound Cordyceps TCM-700C

2 more assets in the full pipeline.

Request access →

Partnerships

General Agent of Taiwan; further details on partnerships are not provided in public sources[1].

Beyond the preview

Go deeper on TCM Biotech International Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCM Biotech International Corp..

Explore the full profile